Clinical Trials on Type2 Diabetes

Total 64505 results

National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
St. Jude Children's Research Hospital
Pfizer; Ipsen

Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Peripheral Primitive Neuroectodermal Tumor | Recurrent Rhabdoid Tumor | Recurrent... and other conditions

United States, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell Carcinoma | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myeloproliferative Neoplasm | Relapsed Follicular Lymphoma | Relapsed T-Cell Lymphoma and other conditions

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome With Excess Blasts | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditions

United States, Israel, Peru
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult Acute... and other conditions

United States
University of Florida
Monteris Medical

Terminated

LITT and Pembrolizumab in Recurrent Brain Metastasis (TORCH)

Melanoma | Primary Mediastinal Large B-Cell Lymphoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Cancer | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Brain Metastases, Adult | Renal Cell... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery

Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
National Cancer Institute (NCI)

Completed

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Juvenile Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Lymphoblastic Leukemia | Prolymphocytic Leukemia | Hairy Cell Leukemia | Acute Undifferentiated Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Childhood Acute Myeloid... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Celldex Therapeutics

Completed

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | Marginal Zone B Cell Lymphoma) | Any T-cell Malignancy | Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma | Hormone-refractory Prostate Adenocarcinoma, Ovarian... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Metastatic Osteosarcoma | Disseminated Neuroblastoma | Previously Treated... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic... and other conditions

United States
National Cancer Institute (NCI)

Not yet recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Squamous Cell Carcinoma of the Penis | Renal Medullary Carcinoma | Squamous Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Urinary Tract | Squamous Cell Carcinoma of the Urinary Tract | Primary Adenocarcinoma of the Bladder | Primary Adenocarcinoma...

United States
Florida International University
National Institute on Minority Health and Health Disparities (NIMHD); Nicklaus... and other collaborators

Recruiting

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Ependymoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Large... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 | Stage IIIB Fallopian Tube Cancer... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Mayo Clinic

Withdrawn

A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation

Head and Neck Carcinoma | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Hypopharyngeal Carcinoma AJCC v8 | Stage IV Laryngeal Cancer AJCC v8 | Stage... and other conditions
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Recurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI); Children's Hospital of Michigan

Terminated

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

Unspecified Childhood Solid Tumor, Protocol Specific | Osteosarcoma | Neuroblastoma | Retinoblastoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | Wilms Tumor and Other Childhood Kidney Tumors | Childhood Choroid Plexus Tumor | Childhood Soft Tissue Sarcoma | Childhood Medulloblastoma | Childhood... and other conditions

United States
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Cutaneous B-cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Adult Grade III Lymphomatoid... and other conditions

United States
Kami Maddocks
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
DxTerity Diagnostics
National Cancer Institute (NCI)

Unknown

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) (RADIANT)

Cancer | Cancer of Liver | Cancer of Pancreas | Cancer of Stomach | Cancer of Cervix | Cancer of Colon | Cancer of Rectum | Cancer of Kidney and Renal Pelvis | Cancer of Prostate | Radiation Therapy | Cancer of Esophagus | Cancer of Ovary | Cancer of Kidney | Cancer of Bladder | Cancer of Gallbladder | Cancer of Anus | Cancer... and other conditions

United States
Northwestern University

Terminated

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Washington University School of Medicine
AstraZeneca

Terminated

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Kidney Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Cancer of the Ovary | Renal Cancer | Colorectal Carcinoma | Ovary Cancer | Cancer of Breast | Gastroesophageal Cancer | Cancer of the Pancreas | Cancer of the Breast | Cancer... and other conditions

United States

Clinical Trials on Type2 Diabetes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations